Table 1—

Potency(pD2) and maximal response (Emax; % total active tone) values for acetylcholine (ACh) in control and different experimental groups of nasal venous vessels at resting tension and raised tone

ControlL-NAMEL-NAME+L-arginine
pD2Emax %pD2Emax %pD2Emax %
LCV ≤10−3 M#6.1±0.19 (9)-10±1.5 (9)-1±1.6* (9)NANA
SCV ≤10−3 M#6.0±0.21 (6)-8±2.5 (6)0±0* (6)NANA
LCV ≥10−2 M#2.3±0.03 (9)+12±2.0 (9)+2.4±0.02 9)19±1.9 (9)*NANA
SCV ≥10−2 M#2.3±0.02 (6)+10±1.2 (6)+2.3±0.03 (6)19±3.6 (6)*NANA
ACV#5.6±0.23 (5)§36±4.4 (5)§5.7±0.18 (5)38±3.9 (5)NANA
DNV#5.7±0.23§ (6)58±2.4§ (6)5.9±3.6 (6)55±6.2 (6)NANA
SPV#4.9±0.12 (8)§35±2.1 (8)§5.2±0.10 (8)34±4.2 (8)NANA
LCV4.7±0.14 (13)+-38±2.0 (13)+4.5±0.19 (5)-11±2.7 (5)*4.7±0.19 (5)-33±2.8 (5)ƒ
SCV4.9±0.21 (12)+-39±3.5 (12)+4.8±0.28 (6)-8±2.3 (6)*5.1±0.20 (5)-35±4.5 (5)ƒ
  • Data are presented as mean±sem (n). L-NAME: nitro-L-arginine-methyl-ester 1×10-5 M; LCV: lateral collecting vein; SCV: septal collecting vein; ACV: anterior collecting vein; DNV: dorsal nasal vein; SPV: sphenopalatine vein; NA: not available. #: vascular segment at resting tension; : vascular segment at raised tone; +: p<0.05 versus LCV and SCV at ≤1×10-3 M ACh at resting tension; §: p<0.05 versus LCV and SCV at ≥1×10-2 M ACh at resting tension. ƒ: p<0.05 versus L-NAME-treated group. *: p<0.05 versus control group. L-arginine was used at a concentration of 3×10-2 M.